Standout Papers

Baricitinib versus Placebo or Adalimumab in... 2006 2026 2012 2019 593
  1. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis (2017)
    Peter C. Taylor, Edward Keystone et al. New England Journal of Medicine
  2. Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate (2006)
    Ravinder N. Maini, Peter C. Taylor et al. Arthritis & Rheumatism
  3. Neutralizing monoclonal antibodies for treatment of COVID-19 (2021)
    Peter C. Taylor, Andrew C. Adams et al. Nature reviews. Immunology
  4. Anti-TNF therapy: past, present and future (2014)
    Claudia Monaco, Jagdeep Nanchahal et al. International Immunology

Immediate Impact

5 by Nobel laureates 5 from Science/Nature 110 standout
Sub-graph 1 of 17

Citing Papers

Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Rheumatoid arthritis
2023 Standout
77 intermediate papers

Works of Peter C. Taylor being referenced

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
2017 Standout
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
2014
and 41 more

Author Peers

Author Last Decade Papers Cites
Peter C. Taylor 7449 3481 4261 444 16.9k
Ernest Choy 8100 3134 3978 347 18.3k
Josef S Smolen 11771 3616 5373 336 19.6k
David L. Scott 8687 3523 2694 402 19.4k
Juan J. Gómez‐Reino 10472 3771 5230 361 19.3k
Daniel Aletaha 14537 5223 4534 318 20.4k
Larry W. Moreland 11918 4910 4650 285 18.4k
Michael H. Weisman 14535 4915 6012 338 21.6k
Hisashi Yamanaka 9241 2466 2694 718 17.1k
Ben A. C. Dijkmans 17930 6033 6125 330 24.4k
Vibeke Strand 14990 5499 6100 514 22.2k

All Works

Loading papers...

Rankless by CCL
2026